Mr. Huitt Tracey reports

NERVGEN PHARMA ANNOUNCES APPOINTMENT OF DR. MATVEY LUKASHEV AS VICE PRESIDENT, RESEARCH AND PRECLINICAL DEVELOPMENT

Nervgen Pharma Corp. has appointed Matvey Lukashev, PhD, as the company's vice-president, research and preclinical development.

"We are delighted to welcome Dr. Lukashev to our team," stated Paul Brennan, president and chief executive officer of Nervgen. "Matvey will lead an important evolution at Nervgen as we emphasize the development of our lead drug candidate, NVG-291, beyond our initial formulation and core indications, and build a pipeline of additional proprietary compounds that address nervous system repair. Matvey has over 20 years of industry experience in discovery and translational research, including 14 years at Biogen where he led target and drug discovery, as well as translational research programs in several therapeutic areas and was responsible for translational research supporting the clinical development of Tecfidera, a multiple sclerosis therapy that reached annual sales over $4-billion. Most recently, Matvey was at the ALS Therapy Development Institute in Massachusetts where he built and led the Augie's Quest Translational Research Center. This experience puts Matvey in an excellent position to lead our research and preclinical development efforts."

"I am excited to be joining Nervgen at this stage of its growth and development," said Dr. Lukashev. "I see tremendous potential for the novel therapeutic modality provided by NVG-291 as we progress through the clinical studies and look forward to supporting the program going forward. Additionally, the learnings we gain during the development of NVG-291 will help us build a pipeline of new therapeutics complementing NVG-291. The field of nervous system repair is a therapeutic area of great unmet medical need where substantial advances can be made to benefit patients suffering from nervous system trauma or neurodegenerative diseases."

Dr. Lukashev has over 30 years of research experience in academia, industry and non-profit biotech settings. Most recently, Dr. Lukashev served as vice-president, translational sciences, at the ALS Therapy Development Institute where he built and led a new translational research and drug discovery function encompassing patient genomics, stem cell biology, genome editing and phenotypic screening for biomarker, target and drug discovery in amyotrophic lateral sclerosis. Prior to joining the ALS Therapy Development Institute, Dr. Lukashev held positions of increasing responsibility at Biogen, where he received the Biogen Idec Outstanding Achievement Award for his leadership of translational studies supporting clinical development of Tecfidera. Dr. Lukashev obtained his doctorate in cell biology from the USSR Academy of Medical Sciences and received postdoctoral training at John Hopkins University and University of California, San Francisco.

About Nervgen Pharma Corp.

Nervgen (TSX-V: NGEN) (OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. Nervgen's lead drug candidate, NVG-291, is currently in a phase 1 clinical trial. The company's initial target indications are spinal cord injury, Alzheimer's disease and multiple sclerosis.

About NVG-291

Nervgen holds the exclusive worldwide rights to NVG-291 and is developing a unique new class of drugs around the technology. NVG-291 is a therapeutic peptide that mimics the intracellular domain of the receptor protein tyrosine phosphatase sigma (PTPsigma), a cell surface receptor known to interact with chondroitin sulphate proteoglycans (CSPGs). Both PTPsigma and CSPGs have been shown to inhibit neural repair mechanisms following nervous system damage. NVG-291-R, the rodent form of NVG-291, has been shown to promote functional recovery and enable nervous system repair in a range of animal models, including models of spinal cord injury, peripheral nerve injury, multiple sclerosis and stroke, through enhanced plasticity, axonal regeneration and remyelination.

We seek Safe Harbor.